Skip to main content
. 2021 Aug 17;8(9):e568–e580. doi: 10.1016/S2352-3018(21)00157-0

Figure 3.

Figure 3

Immunogenicity to SARS-CoV-2 full-length spike and receptor-binding domain proteins

Analyses stratified by HIV status (A) and by SARS-CoV-2 serostatus (B) at baseline in people with HIV. Antibody responses assessed at day 0 (baseline), day 28 (post-priming dose), and day 42 (14 days post-booster dose). Boxes denote interquartile ranges and horizontal bars denote median antibody concentration in BAU/mL. BAU=binding antibody unit.